College of Korean Medicine, Daejeon University, Daejeon.
Department of Neuropsychiatry, College of Oriental Medicine, Kyunghee University, Seoul.
Medicine (Baltimore). 2021 Jun 25;100(25):e26363. doi: 10.1097/MD.0000000000026363.
BACKGROUND: Alzheimer disease (AD) is the most common cause of dementia, which may lead to severe memory loss and other cognitive disorders. Yukmijihwang-tang (YMJ), a type of Korean traditional herbal medicine, has been shown to be effective against neurodegenerative diseases. Although a meta-analysis on the efficacy of YMJ on AD exists, the study had some limitations, and there have been several newly published studies assessing the effect of YMJ. Therefore, the purpose of this study is to evaluate the efficacy and safety of YMJ as a treatment for AD through a meta-analysis. METHODS: A systematic search of the following electronic databases will be conducted to identify eligible studies: MEDLINE (PubMed), Elsevier (EMBASE), The Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Korean Medical Database (KMBASE), Oriental Medicine Advanced Searching Integrated System (OASIS), Korean Traditional Knowledge Portal, Citation Information by NII (CiNii), China National Knowledge Infrastructure (CNKI). All randomized controlled trials assessing the efficacy and safety of YMJ on the symptoms of AD will be included. Two independent reviewers will perform article retrieval, deduplication, data screening, data extraction, quality evaluation, and data analyses using RevMan version 5.4. The Cochrane risk of bias tool will be used to assess the quality of the trials. RESULTS: This study will provide synthesis of the cognitive function measured with neuropsychological tests, behavioral and psychological symptoms of dementia (BPSD), and activities of daily living (ADL) measured using validated scales. The clinical effective rate and adverse events will also be analyzed to assess the efficacy and safety of YMJ for treating AD. CONCLUSION: This systematic review will provide evidence for the efficacy and safety of YMJ in AD. ETHICS AND DISSEMINATION: Ethical approval is not required because individual patient data will not be included in this study. The study findings will be disseminated through conference presentations.
背景:阿尔茨海默病(AD)是痴呆症最常见的病因,可能导致严重的记忆丧失和其他认知障碍。Yukmijihwang-tang(YMJ)是一种韩国传统草药,已被证明对神经退行性疾病有效。尽管之前有一项关于 YMJ 治疗 AD 疗效的荟萃分析,但该研究存在一些局限性,并且已经有几项新发表的研究评估了 YMJ 的疗效。因此,本研究旨在通过荟萃分析评估 YMJ 治疗 AD 的疗效和安全性。
方法:系统检索以下电子数据库以确定合格的研究:MEDLINE(PubMed)、Elsevier(EMBASE)、The Cochrane Central Register of Controlled Trials(CENTRAL)、Cumulative Index to Nursing and Allied Health Literature(CINAHL)、韩国医学数据库(KMBASE)、东方医学高级检索综合系统(OASIS)、韩国传统知识门户、引文信息由 NII(CiNii)、中国国家知识基础设施(CNKI)。将纳入所有评估 YMJ 对 AD 症状疗效和安全性的随机对照试验。两名独立评审员将使用 RevMan 版本 5.4 进行文章检索、去重、数据筛选、数据提取、质量评估和数据分析。将使用 Cochrane 偏倚风险工具评估试验的质量。
结果:本研究将综合评估神经心理测试、行为和心理症状的痴呆(BPSD)以及使用经过验证的量表测量的日常生活活动(ADL)的认知功能。还将分析临床有效率和不良反应,以评估 YMJ 治疗 AD 的疗效和安全性。
结论:本系统评价将为 YMJ 在 AD 中的疗效和安全性提供证据。
伦理与传播:由于本研究不包括个体患者数据,因此不需要伦理批准。研究结果将通过会议报告进行传播。
Medicine (Baltimore). 2021-6-25
Cochrane Database Syst Rev. 2022-2-1
Medicine (Baltimore). 2020-1
Medicine (Baltimore). 2020-8-14
J Alzheimers Dis. 2020
Mol Neurodegener. 2019-8-2
Evid Based Complement Alternat Med. 2018-1-4
BMC Complement Altern Med. 2012-4-20